The 18th Cell Transplant and Regenerative Medicine Society International Congress 2025
Tokyo, Japan
October 22-25, 2025
Attending
Bob McCarthy and Drew Breite will be attending and exhibiting at CTRMS 2025 in Tokyo, Japan from October 22-25, 2025. Drew and Bob will attend the meeting and present posters at the Poster Session on Thursday October 23 on “An ancillary material supplier’s perspective on ISO 20399:2022” and “A rational design method for tissue dissociation enzyme optimization.” The latter presentation applies the concepts from VitaCyte’s model of enzyme-mediated tissue dissociation to simplify optimization of enzyme formulations. Both will be available to discuss technical questions related to the portfolio of VitaCyte products. Look for them at the meeting or reach out directly to set up a time to meet. Don’t forget to grab some merch on the way!
Bob McCarthy
President & Co-Founder
Drew Breite
Director of Quality Assurance
Symposia
VitaCyte is sponsoring a Symposia.
ISO 20399 Standard for Ancillary Materials:
Relevance to Tissue Dissociation Enzymes
Robert McCarthy
Thursday, October 23 | 12:30-13:30
Two published Standards on ancillary materials (AMs) are the US Pharmacopeia (USP) <1043> and ISO 20399 International Standard. The ISO Standard defines AMs as “materials that come in contact with the cellular therapeutic product during cell processing but are not intended to be part of the final product formulation.” This Standard outlines the requirements the AM manufacturer should conform to for qualification as a supplier. The AM supplier is responsible for controlling, documenting, and communicating known aspects of the AM manufacturing process that impact the quality and consistency of the product. VitaCyte has designed manufacturing processes and product testing that align with the criteria that impact AM performance for the intended application. A case study will be presented that demonstrates how the biochemical characteristics of collagenase enzymes affected human islet yields, leading to fewer islet transplants being performed in 2007 as part of the Clinical Islet Transplantation Consortium clinical trial.